Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Study Overview
=================
Brief Summary
-----------------
Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Detailed Description
-----------------
Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.

Official Title
-----------------
Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Radiation: Narrowband Ultraviolet B
* Drug: Acitretin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both sexes with psoriasis vulgaris. Exclusion Criteria: • Patients with history of malignancies, renal and liver diseases. Patients received NB-UVB phototherapy in the last 6 months. Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: NB-UVB group<br>Patients who receive Narrowband ultraviolet B phototherapy | Radiation: Narrowband Ultraviolet B<br>* patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months<br>* Other names: NB-UVB phototherapy;|
| Active Comparator: Acitretin group<br>Patients who receive acitretin | Drug: Acitretin<br>* patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months<br>|
| No Intervention: Control group<br>It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin | This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease PASI score in psoriatic patients | Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin | 3 months |